Selective Inhibition of Glucagon and Insulin Secretion by Somatostatin Analogs
- 1 January 1979
- journal article
- research article
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 160 (1) , 76-79
- https://doi.org/10.3181/00379727-160-40393
Abstract
The effects of somatostatin [SRIF] and 10 structural analogs of SRIF on Ar stimulated glucagon and insulin secretion were studied in isolated rat pancreas perfusions. All analog data were compared with the inhibitory effects of SRIF. It was observed that structural modifications could produce clear cut dissociation of the inhibitory effects on glucagon vs. insulin secretion. Four compounds which seem to have little effect on insulin release, but compared with SRIF have an enhanced inhibitory effect on glucagon release, are of potential interest in the therapy of diabetes. These compounds are DCys14; DTrp8, DCys14; Ala2, DTrp8, DCys14; and C-Gln (Gly)2, DTrp8 somatostatin.This publication has 4 references indexed in Scilit:
- Somatostatin: Analogs with Selected Biological ActivitiesScience, 1977
- A bicyclo-somatostatin analog, highly specific for the inhibition of growth hormone releaseBiochemical and Biophysical Research Communications, 1977
- Somatostatin analogs which inhibit glucagon and growth hormone more than insulin releaseBiochemical and Biophysical Research Communications, 1977
- Dissociation of somatostatin effects. Peptides inhibiting the release of growth hormone but not glucagon or insulin in ratsLife Sciences, 1976